CDMO 3PBIOVIAN officials report that the company has launched the AAVion® platform, a fully integrated adeno-associated virus (AAV) manufacturing solution designed to accelerate gene therapy development. They add that the platform, built around a proprietary HEK293 cell line, unifies the steps of AAV manufacturing into a cohesive process, from vector design and assembly through in-house plasmid production and cell banking to upstream processing, downstream purification, quality control (QC), release analytics, and aseptic fill & finish.
The purification process has been designed to obtain high titers and purities with multiple AAV serotypes, without major optimization, says Pirkko Kortteinen, COO, who notes that 3PBIOVIAN also offers clinical labeling and direct delivery of AAV drug product to clinical sites.
“With this comprehensive platform approach, clients benefit from a clear, consolidated workflow and a trusted partner capable of managing every phase of AAV manufacturing and clinical supply under one roof,” he continues.
In addition to complementing AAV manufacturing, the company’s Plasmid DNA (pDNA) platform is now available as a standalone service. This platform approach, covering research-grade to GMP-grade plasmids, is designed to meet the increasing demand for plasmid DNA, not only for AAV viral vector production, but also for other advanced therapeutic applications such as mRNA, cell therapy, and vaccines, according to Kortteinen.
The post 3PBIOVIAN Introduces Two Platforms for AAV and pDNA Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.
The purification process has been designed to obtain high titers and purities with multiple AAV serotypes, without major optimization, says Pirkko Kortteinen, COO, who notes that 3PBIOVIAN also offers clinical labeling and direct delivery of AAV drug product to clinical sites.
“With this comprehensive platform approach, clients benefit from a clear, consolidated workflow and a trusted partner capable of managing every phase of AAV manufacturing and clinical supply under one roof,” he continues.
In addition to complementing AAV manufacturing, the company’s Plasmid DNA (pDNA) platform is now available as a standalone service. This platform approach, covering research-grade to GMP-grade plasmids, is designed to meet the increasing demand for plasmid DNA, not only for AAV viral vector production, but also for other advanced therapeutic applications such as mRNA, cell therapy, and vaccines, according to Kortteinen.
The post 3PBIOVIAN Introduces Two Platforms for AAV and pDNA Manufacturing appeared first on GEN - Genetic Engineering and Biotechnology News.